

Elisa Cappuzzello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/829687/publications.pdf>

Version: 2024-02-01

10
papers

430
citations

1307594

7
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

872
citing authors

#	ARTICLE	IF	CITATIONS
1	Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. , 2021, 9, e002475.		6
2	A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks. Cytotherapy, 2020, 22, 511-518.	0.7	6
3	Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. OncoImmunology, 2020, 9, 1777046.	4.6	24
4	Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity. Methods in Molecular Biology, 2018, 1827, 381-397.	0.9	7
5	Glucocorticoid receptor signalling activates YAP in breast cancer. Nature Communications, 2017, 8, 14073.	12.8	129
6	Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells. Cytokine and Growth Factor Reviews, 2017, 36, 99-105.	7.2	37
7	A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. Nature Communications, 2017, 8, 15772.	12.8	102
8	Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. OncoImmunology, 2017, 6, e1313371.	4.6	11
9	Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy. Transfusion Medicine and Hemotherapy, 2017, 44, 327-336.	1.6	87
10	Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. OncoImmunology, 2016, 5, e1199311.	4.6	21